This study aims to assess the efficacy of the efficacy and safety of investigational drug
(NanoS) in patients with mild to moderate COVID-19 at high risk for progression to severe
COVID-19, including death.
Phase:
Phase 3
Details
Lead Sponsor:
General Administration of Military Health, Tunisia